Cambridge, MA, United States
Cambridge, MA, United States

Time filter

Source Type

Patent
Millennium Pharmaceuticals Inc. | Date: 2015-04-21

The invention relates to antibody molecules which bind pSYK, and methods for using the same for diagnosis, prognosis, to select patients for treatment with a SYK-targeted therapy, or evaluate the pharmacodynamic profile of a SYK-targeted therapy.


Patent
Millennium Pharmaceuticals Inc. | Date: 2016-11-09

The present invention provides a compound of formula I: and pharmaceutically acceptable salts thereof, wherein X, R^(1), R^(2), R^(3), R^(4), R^(5), L^(1), L^(2), m, and n, are as described in the specification. Such compounds are inhibitors of VPS34 and thus useful for treating proliferative, inflammatory, or cardiovascular disorders.


Patent
Millennium Pharmaceuticals Inc. | Date: 2016-05-04

Antibodies and antigen-binding fragments of antibodies that bind human CXCR3 are disclosed. In preferred embodiments, the antibodies are human. Nucleic acids and vectors encoding the antibodies or portions thereof, recombinant cells that contain the nucleic acids, and compositions comprising the antibodies or antigen-binding fragments are also disclosed. The invention also provides therapeutic and diagnostic methods which employ the antibodies and antigen-binding fragments.


Patent
Millennium Pharmaceuticals Inc. | Date: 2016-08-29

This invention relates to compounds that inhibit E1 activating enzymes, pharmaceutical compositions comprising the compounds, and methods of using the compounds. The compounds are useful for treating disorders, particularly cell proliferation disorders, including cancers, inflammatory and neurodegenerative disorders; and inflammation associated with infection and cachexia.


Patent
Millennium Pharmaceuticals Inc. | Date: 2016-07-20

Methods for inducing clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human 47 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-47 antibody in vivo.


The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.


Patent
Millennium Pharmaceuticals Inc. and Sunesis Pharmaceuticals | Date: 2016-09-21

The present invention provides compounds useful as inhibitors of PDK1. The present invention also provides compositions thereof, and methods of treating PDK1-mediated diseases.


Patent
Millennium Pharmaceuticals Inc. | Date: 2016-01-19

Antibodies and antigen-binding fragments of antibodies that bind GCC are disclosed. The invention also provides therapeutic and diagnostic methods utilizing the antibodies and antigen-binding fragments provided herein.


Patent
Millennium Pharmaceuticals Inc. | Date: 2016-02-25

The present invention relates to methods for the treatment of hematological malignancies. In particular, the invention provides methods for treatment of hematological malignancies by administering Aurora kinase inhibitors in combination with anti-CD20 antibodies.


Patent
Millennium Pharmaceuticals Inc. | Date: 2016-07-20

Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human 47 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-47 antibody in vivo.

Loading Millennium Pharmaceuticals Inc. collaborators
Loading Millennium Pharmaceuticals Inc. collaborators